The company currently holds 106.24
M in liabilities with Debt to Equity (D/E) ratio of 0.46, which is about average as compared to similar companies. Meridian Bioscience has a current ratio of 3.93, suggesting that it is liquid enough and is able to pay its financial obligations when due. Meridian Bioscience is UNDERVALUED at 21.55 per share with modest projections ahead.
We determine the current worth of Meridian Bioscience using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Meridian Bioscience based exclusively on its
fundamental and basic
technical indicators. By analyzing Meridian Bioscience's
financials, quarterly and monthly indicators, and related drivers such as
dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of
Meridian Bioscience's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Meridian Bioscience. We calculate exposure to Meridian Bioscience's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to Meridian Bioscience's related companies.
Meridian Bioscience Investment Alerts
Meridian investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Meridian Bioscience performance across your portfolios.Please check all
investment alerts for Meridian
Meridian Bioscience Valuation Ratios as Compared to Competition
Our valuation model uses many indicators to compare Meridian value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Meridian Bioscience competition to find
correlations between indicators driving the intrinsic value of Meridian.
Another angle On Meridian Bioscience
The entity reported the previous year's revenue of 240.36
M. Net Income was 43.8
M with profit before overhead, payroll, taxes, and interest of 118.33
M.
Margins Breakdown
Meridian profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or Meridian Bioscience itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of Meridian Bioscience profit margins.
| Operating Margin | 24.03 |
| EBITDA Margin | 29.09 |
| Gross Margin | 71.72 |
| Profit Margin | 16.72 |
Meridian Bioscience Revenue Per Employee is quite stable at the moment. Moreover, Meridian Bioscience Earnings Before Interest Taxes and Depreciation Amortization EBITDA is quite stable at the moment.
Will Meridian Bioscience latest rise continue?
Latest kurtosis is at 2.98. Meridian Bioscience exhibits very low volatility with skewness of -1.3 and kurtosis of 2.98. However, we advise investors to further study Meridian Bioscience technical indicators to make sure all market info is available and is reliable.
Our Bottom Line On Meridian Bioscience
When is the right time to buy or sell Meridian Bioscience? Buying stocks such as Meridian Bioscience isn't very hard. However, what challenging for most investors is doing it at the right time. Proper market timing is something most people cannot do without
sophisticated tools, which help to isolate the right opportunities, deliver winning trades and diversify portfolios on a daily bases. With a somewhat neutral outlook on your 30 days horizon, it may be better to hold off any trading activity and neither take over new shares of Meridian nor trade your existing holdings in the Stock. It seems the expected volatility has not yet been fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Meridian Bioscience.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Meridian Bioscience. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
